Abstract
SUMMARYThe clinical efficacy of a combined immediate‐release and sustained‐release preparation of isosorbide‐5‐mononitrate for angina pectoris is observed within a few minutes of administration. The preparation reduces the number of silent and painful ischaemic episodes and increases work and exercise capacity. The pharmacokinetic profiles accord with the circadian variation in cardiovascular disease. Drug levels fall significantly at night and tolerance to the haemodynamic and antianginal effects is not seen. Once‐daily administration is appreciated by patients. The preparation also shows promise in treating heart failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
